H. Lichenstein

发表

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

P. Finn, M. Sehested, M. Jeffers, 2008, The Biochemical journal.

Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS

M. Wurfel, J. Kane, S. Wright, 1994, The Journal of experimental medicine.

Neutrophil Activation by Bacterial Lipoprotein Versus Lipopolysaccharide: Differential Requirements for Serum and CD141

J. Peterson, N. Qureshi, Hongwei H Zhang, 2000, The Journal of Immunology.

Soluble CD14(1-152) confers responsiveness to both lipoarabinomannan and lipopolysaccharide in a novel HL-60 cell bioassay.

M. Volta, E. Soprana, D. Vercelli, 1998, Journal of immunology.

Identification of stathmin as a novel substrate for p38 delta.

T. Kohno, X. Wang, K. Diener, 1998, Biochemical and biophysical research communications.

Biological responses to PDGF-BB versus PDGF-DD in human mesangial cells.

I. Behrmann, J. Floege, F. Strutz, 2006, Kidney international.

Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.

M. Jeffers, H. Lichenstein, Frank Wu, 2002, Cancer research.

Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14

M. Wurfel, D. Johnson, M. Kelley, 1994, The Journal of experimental medicine.

Secretion of interleukin-1 beta and Escherichia coli galactokinase by Streptomyces lividans

P. Young, P. Simon, T. Eckhardt, 1988, Journal of bacteriology.

Purification and activation of recombinant p38 isoforms alpha, beta, gamma, and delta.

D. Johnson, H. Yamane, J. Hunt, 1998, Protein expression and purification.

Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB

M. Jeffers, H. Lichenstein, M. Torgov, 2007, Cancer Chemotherapy and Pharmacology.

Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14.

M. C. Hu, M. Kelley, S. Wright, 1996, Journal of immunology.

CD14Differential Requirements for Serum and Lipoprotein Versus Lipopolysaccharide: Neutrophil Activation by Bacterial

J. Peterson, N. Qureshi, Hongwei H Zhang, 2000 .

Effects of recombinant soluble CD14 on association of bacterial lipopolysaccharide with bovine alveolar macrophages in vitro

Z. Yang, P. Bochsler, H. Lichenstein, 1997 .

Identification of a Domain in Soluble CD14 Essential for Lipopolysaccharide (LPS) Signaling but Not LPS Binding (*)

M. Kelley, S. Wright, H. Lichenstein, 1995, The Journal of Biological Chemistry.

Lipopolysaccharide ( LPS )-binding Protein Accelerates the Binding o f LPS to CD 14 By

M. Wurfel, H. Lichenstein, David A. Johnson, 2003 .

Dual effects of soluble CD14 on LPS priming of neutrophils

A. Troelstra, B. Giepmans, J. Verhoef, 1997, Journal of leukocyte biology.

Identification of a Lipopolysaccharide Binding Domain in CD14 between Amino Acids 57 and 64 (*)

M. Kelley, L. Narhi, S. Wright, 1995, The Journal of Biological Chemistry.

A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis.

B. Keyt, J. Peterson, F. Eitner, 2003, Journal of the American Society of Nephrology : JASN.

Soluble CD14 promotes LPS activation of CD14-deficient PNH monocytes and endothelial cells.

D. Golenbock, H. Lichenstein, C. Moldow, 1995, The Journal of laboratory and clinical medicine.

Cloning and characterization of a gene encoding extracellular metalloprotease from Streptomyces lividans.

L. Narhi, G. Smith, H. Lichenstein, 1992, Gene.

Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein gene family.

M. Wurfel, J. Mayer, D. Johnson, 1994, The Journal of biological chemistry.

Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis.

J. Peterson, M. Jeffers, S. Sonis, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preclinical Characterization of CG 53135 ( FGF-20 ) in Radiation and Concomitant Chemotherapy / Radiation-induced Oral Mucositis

J. Peterson, M. Jeffers, S. Sonis, 2003 .

Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase

C. Manthey, H. Lichenstein, S.-W. Wang, 1999, Inflammation Research.

Influence of CD 14, LBP and BPI in the Monocyte Response to LPS of Different Polysaccharide Chain Length

T. Espevik, A. Sundan, H. Lichenstein, 1995, Scandinavian journal of immunology.

Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B

H. Lichenstein, Yanfang Pan, H. Dang, 2022, Hepatology.

Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses

S. Wright, H. Lichenstein, T. Kusunoki, 1995, The Journal of experimental medicine.

Repression and catabolite gene activation in the araBAD operon

H. Lichenstein, E. Hamilton, N. Lee, 1987, Journal of bacteriology.

Endotoxin receptors (CD14) are found with CD16 (Fc gamma RIII) in an intracellular compartment of neutrophils that contains alkaline phosphatase.

P. Detmers, H. Lichenstein, M. Kelley, 1995, Journal of immunology.

The P-selectin glycoprotein ligand from human neutrophils displays sialylated, fucosylated, O-linked poly-N-acetyllactosamine.

R. Cummings, H. Lichenstein, K. Moore, 1994, The Journal of biological chemistry.

Cloning and nucleotide sequence of the N-acetylmuramidase M1-encoding gene from Streptomyces globisporus.

E. Mendiaz, H. Lichenstein, M. Rohde, 1990, Gene.

PDGF-D, a new protease-activated growth factor

J. Rothberg, Meijia Yang, R. Shimkets, 2001, Nature Cell Biology.

Angioarrestin: an antiangiogenic protein with tumor-inhibiting properties.

Meijia Yang, R. Shimkets, M. Jeffers, 2002, Cancer research.

Identification of a novel human fibroblast growth factor and characterization of its role in oncogenesis.

R. Shimkets, M. Jeffers, M. Yang, 2001, Cancer research.

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer

M. Jeffers, Xiaozhong Qian, E. Mills, 2008, International journal of cancer.

Fibroblast growth factors in cancer: therapeutic possibilities

M. Jeffers, H. Lichenstein, W. Larochelle, 2002, Expert opinion on therapeutic targets.

Molecular Cloning and Characterization of a Novel Protein Kinase with a Catalytic Domain Homologous to Mitogen-activated Protein Kinase Kinase Kinase*

K. Diener, H. Lichenstein, D. Trollinger, 1996, The Journal of Biological Chemistry.

Molecular Cloning and Characterization of a Novel p38 Mitogen-activated Protein Kinase*

C. Manthey, J. Delaney, K. Diener, 1997, The Journal of Biological Chemistry.

Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer

R. Glasspool, D. Dizon, P. Celano, 2012, International Journal of Gynecologic Cancer.

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Damon L. Meyer, M. Jeffers, B. Kuang, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

J. Rothberg, Tian Xu, S. Halene, 2019, Blood.

Cancer Therapy : Preclinical

M. Jeffers, B. Kuang, F. Boldog, 2006 .

Kinase Suppressor of Ras Is Ceramide-Activated Protein Kinase

R. Kolesnick, S. Basu, Bei Yao, 1997, Cell.

A novel human fibroblast growth factor treats experimental intestinal inflammation.

Meijia Yang, M. Jeffers, R. Sartor, 2002, Gastroenterology.

Identification and Characterization of a Pro-tumor Necrosis Factor-α-processing Enzyme from the ADAM Family of Zinc Metalloproteases*

M. T. Brewer, T. Kohno, H. Lichenstein, 1997, The Journal of Biological Chemistry.

Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide-binding protein, CD14, and bactericidal/permeability-increasing factor

G. Skjåk-Bræk, G. Skjåk‐Braek, T. Espevik, 1997, Infection and immunity.

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

M. Sehested, M. Jeffers, Xiaozhong Qian, 2006, Molecular Cancer Therapeutics.

Angioarrestin: a unique angiopoietin-related protein with anti-angiogenic properties.

M. Jeffers, H. Lichenstein, W. Larochelle, 2005, Biochemical and biophysical research communications.

P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin

R. Cummings, D. Johnson, R. Bruehl, 1995, The Journal of cell biology.

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.

Paul Beckett, Jonathan Rothberg, J. Rothberg, 2017, Blood.

LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.

J. Rothberg, M. Andreeff, Tian Xu, 2019, Blood advances.

Diphosphoryl lipid A from Rhodobacter sphaeroides inhibits complexes that form in vitro between lipopolysaccharide (LPS)-binding protein, soluble CD14, and spectrally pure LPS

N. Qureshi, H. Lichenstein, B. Jarvis, 1997, Infection and immunity.

Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis

Enrique Alvarez, M. Jeffers, F. Boldog, 2005, Cancer biology & therapy.

Soluble CD14 Truncated at Amino Acid 152 Binds Lipopolysaccharide (LPS) and Enables Cellular Response to LPS (*)

David A. Johnson, M. Kelley, S. Wright, 1995, The Journal of Biological Chemistry.

Activity of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Preclinical Studies and in a Phase I Study in Patients with Advanced Haematological Tumors.

M. Sehested, M. Jeffers, L. Knudsen, 2005 .

Molecular Cancer Differential Effects of Class I Isoform Histone Deacetylase Depletion and Enzymatic Inhibition by Belinostat or Valproic Acid in Hela Cells

T. Litman, M. Sehested, M. Jeffers, 2022 .

Molecular Cloning and Characterization of a Novel p 38 Mitogen-activated Protein Kinase *

C. Manthey, J. Delaney, K. Diener, 1997 .

Identi fi cation of apilimod as a fi rst-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma

J. Rothberg, Tian Xu, Meiling Zheng, 2017 .

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

S. Ansell, L. Miller, H. Lichenstein, 2017 .

CD14: Physical Properties and Identification of an Exposed Site That Is Protected by Lipopolysaccharide (*)

L. Narhi, S. Wright, M. Mcginley, 1995, The Journal of Biological Chemistry.

Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14

M. Wurfel, H. Lichenstein, David A. Johnson, 1994, The Journal of experimental medicine.